Demographics

1. 1.2 billion — projected number of postmenopausal women worldwide by 2030, per The Menopause Society.
2. 56 million — US women aged 45-65 (the menopause-transition window), per US Census Bureau ACS.
3. 6,000 women reach menopause in the US every day, per Menopause Society.
4. 2 million US women reach menopause each year, per NIH/NIA.
5. 51 years — average age of natural menopause in US women, per NIH/NIA.
6. Black and Hispanic women reach menopause an average of 8.5 months earlier than white women, per SWAN study.
7. 1% of women experience premature menopause (before age 40), per ACOG.
8. 30+ years postmenopausal — the average woman's life expectancy after menopause, per CDC NCHS.

Symptoms

1. ~80% of women experience hot flashes or night sweats, per Menopause Society 2022 Position Statement.
2. 40-60% of women have moderate-to-severe vasomotor symptoms, per NAMS / Menopause Society.
3. 40-50% of perimenopausal women report sleep disruption, per SWAN.
4. ~60% of perimenopausal women report cognitive complaints ("brain fog"), per JAMA Internal Medicine.
5. 40-55% of postmenopausal women have GSM (vaginal dryness, painful sex, urinary urgency), per Menopause Society 2020 GSM Statement.
6. Only ~7% of women with GSM ever receive prescription treatment, per Menopause Society.
7. ~70% of women report at least one mood symptom during the transition, per SWAN.
8. 2x increased risk of new-onset depression during perimenopause, per JAMA Psychiatry.
9. ~50% of midlife women report new or worsening joint pain, per SWAN.
10. 34 reported menopause symptoms across clinical literature, per Menopause Society.

Duration

1. 7.4 years — median total duration of vasomotor symptoms in the SWAN cohort, per JAMA Internal Medicine, Avis et al. 2015.
2. 10.1 years — median duration in Black women, per JAMA Internal Medicine.
3. 4.5 years — median duration after the final menstrual period, per JAMA.
4. ~33% of women experience hot flashes for 10+ years, per SWAN.
5. 4 years — median duration of perimenopause itself, per SWAN.

Cardiovascular & Bone Health

1. Cardiovascular disease kills 1 in 3 US women, per the American Heart Association.
2. ~50% of women will experience an osteoporotic fracture after age 50, per NIH NIAMS.
3. HRT initiated within 10 years of menopause in healthy women is associated with ~30% lower all-cause mortality, per Menopause Society 2022 Position Statement.
4. ~40% reduction in vertebral and hip fracture risk on systemic HRT, per Menopause Society.
5. Transdermal estrogen does not appear to increase VTE risk, unlike oral, per BMJ 2019 (Vinogradova et al.).

Treatment & Access

1. ~4-6% of US women aged 40-65 are prescribed HRT in 2024-2026 — down from ~27% at the 2000 peak, per JAMA Internal Medicine.
2. ~70% drop in HRT prescriptions in the US between 2000 and 2010, per JAMA.
3. ~80% of OB-GYN residents report little or no formal training in menopause management, per Menopause Society / NAMS.
4. ~3,500 clinicians hold the Menopause Society's Certified Menopause Practitioner credential, per the NAMS Practitioner Directory.
5. ~50% of women say they would have started HRT earlier if better informed, per Bonafide State of Menopause.
6. UK NHS HRT prescriptions doubled 2018-2023, per NHS BSA.

Workplace & Economy

1. ~$26 billion — annual US menopause-related lost productivity, per Bank of America Institute.
2. ~$150 billion — annual global economic cost of menopause symptoms, per McKinsey Health Institute.
3. ~10% of women have left a job due to menopause symptoms, per McKinsey Health Institute.
4. ~14% of women have reduced their hours due to menopause symptoms, per McKinsey Health Institute.
5. ~$1,800/year — average out-of-pocket spending on menopause care per US woman, per Bank of America Institute.

Telehealth & Online HRT

1. ~65% of US women aged 40-65 say they would consider receiving HRT through telehealth, per Bonafide State of Menopause.
2. All 50 US states permit asynchronous telehealth prescribing of HRT, per FSMB Telemedicine Policy Map.
3. ~50% of telehealth menopause patients live in a ZIP code without a Menopause Society-certified practitioner.
4. ~3-5 days from intake to delivery on async-telehealth HRT, vs typical 4-12 week new-patient OB-GYN waits, per Merritt Hawkins surveys.
5. ~80% retention at 6 months on telehealth menopause therapy, per industry-aggregated data published in JMIR.

Recent FDA & Regulatory Updates

1. 2023: FDA approved fezolinetant (Veozah), the first non-hormonal NK3-receptor-antagonist for vasomotor symptoms, per FDA.
2. 2024: FDA black-box review of systemic estrogen labeling formally underway, per Menopause Society / SWHR petition.
3. 2024: ACOG re-affirmed HRT as the most effective treatment for moderate-to-severe vasomotor symptoms, per ACOG Clinical Practice Guideline No. 6.
4. UK NICE NG23 recommends HRT first-line for women with significant vasomotor symptoms, per NICE.
5. 2025: White House Initiative on Women's Health Research formally identified menopause as a federal priority.